Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 15, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the "Company"), received written notice (the "Notice") from the Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Staff believes that the Company is a "public shell" and that the continued listing of its securities is no longer warranted. The Staff stated that this serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market.

The Notice is formal notification that the Nasdaq Hearings Panel (the "Panel") will consider this matter in rendering a determination regarding the Company's continued listing on The Nasdaq Capital Market. The Company intends to present its views with respect to this additional deficiency at its Panel hearing, scheduled for April 29, 2025.